Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Dihydrospirorenone as an antiandrogen|
|Abstract:||Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for treatment of androgen-induced disorders and/or for contraception.|
|Inventor(s):||Beier; Sybille (Berlin, DE), Elger; Walter (Berlin, DE), Nishino; Yukishige (Berlin, DE), Wiechert; Rudolf (Berlin, DE)|
|Assignee:||Schering Aktiengesellschaft (Berlin, DE)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Germany||39 16 112.9||May 16, 1989|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||154881||<disabled in preview>|
|Australia||5509490||<disabled in preview>|
|Australia||642876||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.